News
BMS and Dragonfly Therapeutics Announce Exclusive Global License for Dragonfly’s IL-12 Investigational Immunotherapy Program
Bristol Myers Squibb and Dragonfly Therapeutics, Inc. announced that they have entered into a definitive agreement under which Bristol Myers Squibb will be granted the global exclusive license to Dragonfly’s interleukin-12 (IL-12) investigational immunotherapy program, including its extended half-life...
Clinical Trials
Qu Biologics Initiates Phase 2 Study to Assess Activation of Anti-cancer Immune Response in Colon Cancer
Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is pleased to announce approval from the Israeli Ministry of Health to proceed with their clinical trial...
Clinical Trials
DSG and Bestat Partner in Building COVID-19 Clinical Trials in Singapore
DSG, Inc., a global leader of eClinical software solutions and services for the life sciences industry along with their CRO partner, Bestat Pharmaservices Corp. (Bestat) are building studies to support COVID-19 treatments and vaccines in Asia. This includes a...
News
Roche and Regeneron collaborate to significantly increase global supply of REGN-COV2 investigational antibody combination for COVID-19
Roche and Regeneron announced that they are joining forces in the fight against COVID-19 to develop, manufacture and distribute REGN-COV2, Regeneron’s investigational antiviral antibody combination, to people around the globe. REGN-COV2 could provide a much-needed treatment option for people...
Drug Research
Novo Nordisk invests DKK 850 million in production facilities in Kalundborg
Novo Nordisk announced plans to invest DKK 850 million in expanding its production facilities in Kalundborg, Denmark. This new investment brings Novo Nordisk’s total investments in site Kalundborg to more than DKK 2 billion in 2020. Novo Nordisk currently...
News
Lilly and Innovent Announce Global Expansion of TYVYT Licensing Agreement
Eli Lilly and Company and Innovent Biologics, Inc. announced a global expansion of their strategic alliance for TYVYT® (sintilimab injection), an anti-PD-1 monoclonal antibody immuno-oncology medicine that was co-developed by Innovent and Lilly in China.
In 2019, Lilly and Innovent...
Drug Research
Indian government starts talks to procure COVID-19 vaccine
Covid-19 vaccines being developed by UK’s Oxford-AstraZeneca and United States’s Moderna-NIAID are the top candidates India is looking at for possible acquisition discussions, senior government officials aware of the country’s vaccine strategy said, adding that a group of experts...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read